The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A network meta-analysis assessing the comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer.
Aiko Nagayama
Employment or Leadership Position - Chugai Pharma (I); Roche (I,U)
Stock Ownership - Chugai Pharma (B)
Tetsu Hayashida
No relevant relationships to disclose
Koji Okabayashi
No relevant relationships to disclose
Hiromitsu Jinno
No relevant relationships to disclose
Maiko Takahashi
No relevant relationships to disclose
Tomoko Seki
No relevant relationships to disclose
Akiko Matsumoto
No relevant relationships to disclose
Takeshi Murata
No relevant relationships to disclose
Yuko Kitagawa
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Other Remuneration - Chugai Pharma